Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients
Parikh, R., Du, X. L., Morgan, R. O., & Lairson, D. R. (2016). Cost Effectiveness of Treatment Sequences for Elderly Metastatic Colorectal Cancer Patients: A Seer-Medicare-Based Modelling Analysis [MEETING ABSTRACT PCN91]. Value in Health, 19(3), A150-A150. DOI: 10.1016/j.jval.2016.03.1590
Treatment sequences with bevacizumab at first-line and targeted biologics at third-line may not be cost-effective at the commonly used threshold of $100,000/QALY gained but a marginal decrease in the cost of bevacizumab may make treatment sequences with first-line bevacizumab cost-effective. Future economic evaluations should validate the study results using parameters from ongoing clinical trials.